{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"3","value":"1.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"To evaluate time to hematologic response. Partial response is defined as a dFLC decrease of ≥ 50%, but remaining \\> 4.0 mg/dL.\n\nVery good partial response is defined as the difference between involved and uninvolved FLCs \\[dFLC\\] \\< 4.0 mg/dL.\n\nComplete response is defined as laboratory values within the normal range free light chain (FLC) ratio (0.25 - 1.65) and negative serum and urine immunofixation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Isatuximab"}],"paramType":"MEDIAN","populationDescription":"Of the 35 analyzable participants, 27 achieved a response.","reportingStatus":"POSTED","timeFrame":"From registration to time of confirmed hematologic progression","title":"Time to Hematologic Response","type":"SECONDARY","unitOfMeasure":"Months"}